No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
DARE Dare Bioscience
- 3.6800
- +0.3200+9.52%
Close Jul 12 16:00 ET
31.00MMarket Cap-929P/E (TTM)
3.7377High3.3700Low36.26KVolume3.3700Open3.3600Pre Close128.18KTurnover0.44%Turnover RatioLossP/E (Static)8.42MShares9.576052wk High-2.81P/B30.49MFloat Cap3.050052wk Low--Dividend TTM8.29MShs Float1304.4000Historical High--Div YieldTTM10.94%Amplitude3.0500Historical Low3.5350Avg Price1Lot Size
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Trading Halt: Halt Status Updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
Express News | Trading Halt: Halted at 7:50:00 P.m. ET - Trading Halt: Halt News Pending
Dare Bioscience To Carry Out 1-for-12 Reverse Stock Split On July 1st, 2024
June 27th (Eastern Time) - $Dare Bioscience(DARE.US)$ is about to implement a 1-for-12 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from July 1st, 2024.$Dare
Express News | Dare Bioscience Shares Are Trading Lower After the Company Announced a 1-for-12 Reverse Stock Split
Express News | Dare Bioscience Inc - Implements 1-for-12 Reverse Stock Split
Dare Bioscience: Split Intended to Increase Bid Price of Common Stk to Enable Co to Regain Compliance With $1 Minimum Bid Price Requirement for Continued Listing on Nasdaq Cap Market >DARE
Dare Bioscience: Split Intended to Increase Bid Price of Common Stk to Enable Co to Regain Compliance With $1 Minimum Bid Price Requirement for Continued Listing on Nasdaq Cap Market >DARE
Comments
$Dare Bioscience(DARE.US$ 11 hours ago it was a 1-12 R/S! Now 7 minutes ago a PR says its a 1-17 R/S?? Hehehe! Make up your mind! Hehehe
5
$Dare Bioscience(DARE.US$ Daré Bioscience Announces Publication Of Phase 2b Study Efficacy Results Of Topical Sildenafil Cream, 3.6% For The Treatment Of Female Sexual Arousal Disorder In Obstetrics & Gynecology
Benzinga
Phase 2b study demonstrated topical Sildenafil Cream, 3.6% improved outcomes among women with female sexual arousal disorder (FSAD), particularly in an exploratory subset of women with FSAD with or without concomitant decreased desire
There are currently no FDA-approved ...
Benzinga
Phase 2b study demonstrated topical Sildenafil Cream, 3.6% improved outcomes among women with female sexual arousal disorder (FSAD), particularly in an exploratory subset of women with FSAD with or without concomitant decreased desire
There are currently no FDA-approved ...
$Dare Bioscience (DARE.US)$ HEAVENLY FATHER in the name of JESUS CHRIST I PRAY THAT THIS WICKED COMPANY STOP AND COME TO NOTHING DEVIL YOU ARE LIAR. GOD YIU GIVE LIFE . LORD BRING THIS EVIL COMPANY TO NOT BE EXISTING NO MORE AND ANY OF ITS SISTER COMPANY THIS I PRAY YOUR HOLY MAN OF GOD. AMEN. SO BE IT
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Sean Parker : I had to end up selling. I got out at .45 thankfully. not much profit made, but profit none the less lol.
TrytosaveabitOP Sean Parker: Any profit is always better than a loss! I did the same! You can bet after R/S I will be looking to get back in!
Sean Parker : same here. I didn't think with all the good news it would come to a r/s honestly. I had this one for months so when it finally got over what I paid, I got out.
TrytosaveabitOP Sean Parker: Again! If it wasn’t for SS’s. It woulda never come to it. I firmly believe that
J L 7 2 : Whether it's 12 or 17, the most important thing is that rs will rise